• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Russia Pharmaceuticals and Healthcare Report Q3 2009 - Product Image

Russia Pharmaceuticals and Healthcare Report Q3 2009

  • Published: July 2009
  • Region: Russia
  • 93 Pages
  • Business Monitor International

The Russia Pharmaceuticals and Healthcare Report provides industry professionals and strategists, corporate analysts, pharmaceutical associations, government departments and regulatory bodies with independent forecasts and competitive intelligence on Russia's pharmaceuticals and healthcare industry.

Russia’s overall macroeconomic situation has stabilised markedly since the end of Q109 – most notably as the ruble’s managed devaluation earlier in the year did not turn into a rout for the currency, or consume all of the country’s stability fund. Still, in US dollar terms, 2009 will be a tough year for the Russian pharmaceutical market, with the author currently predicting a 13.9% contraction, while in ruble terms the market will grow by 15.9%. Much of this growth will be price inflation, and volume consumption will remain stagnant or fall – both worrying signs and likely to spur heavy handed regulation. The author’s current forecast sees a 7.83% compound annual growth rate (CAGR) for 2008 to 2013, with the market expected to reach a value of US$23.4bn by the end of 2013.

Not unusually, the state has resorted to a number of administrative READ MORE >

Executive Summary

SWOT Analysis

Russia Political SWOT
Russia Economic SWOT
Russia Business SWOT
Russia Pharmaceuticals And Healthcare Industry SWOT

Pharmaceutical Business Environment Ratings

Table: Business Environment Ratings
Limits of Potential Returns
Risk to Realisation of Returns
Russia – Market Summary

Regulatory Regime

Intellectual Property Environment
Pricing and Reimbursement Issues
Industry Developments

Industry Forecast Scenario

Overall Market Forecast
Table: Russia’s Drug Market Expenditure Data And Forecasts, 2006 – 2013
Key Growth Factors – Industry
Key Growth Factors – Macroeconomic
Table: Russia – Economic Activity, 2005-2013
OTC Market Forecast
Table: Russia’s OTC Market Data And Forecasts, 2006-2013 (US$mn unless otherwise stated)
Prescription Market Forecast
Table: Russia’s Prescription Market Data And Forecasts, 2006-2013 (US$mn unless otherwise stated)
Generics Market Forecast
Table: Russia’s Generics Market Data And Forecasts, 2006-2013
Export/Import Forecasts
Table: Russia’s Pharmaceuticals Exports And Imports Data And Forecasts, 2006-2013 (US$mn)
Medical Devices
Table: Russia’s Medical Device Market Data And Forecasts, 2006-2013 (US$bn unless otherwise stated)
Other Healthcare Data Forecasts
Table: Russia’s Healthcare Data And Forecasts, 2006-2013
Key Risks to Our Forecast Scenario

Competitive Landscape

Manufacturing Sector
Wholesale Sector
Retail Sector
Company Monitor
Berlin-Chemie/Menarini Pharma GmbH
Gedeon Richter
Krka
Lek (Novartis/Sandoz)
Stada AG (Stada CIS)
Verofarm

Country Snapshot: Russia Demographic Data

Section 1: Population
Table: Demographic Indicators, 2005-2030
Table: Rural/Urban Breakdown, 2005-2030
Section 2: Education and Healthcare
Table: Education, 2002-2005
Table: Vital Statistics, 2005-2030
Section 3: Labour Market and Spending Power
Table: Employment Indicators, 2001-2006
Table: Consumer Expenditure, 2000-2012 (US$)
Table: Average Annual Wages, 2000-2006

Our Forecast Modelling

How We Generate Our Pharmaceutical Industry Forecasts
Pharmaceutical Business Environment Ratings Methodology
Ratings Overview
Table: Pharmaceutical Business Environment Indicators
Weighting
Table: Weighting Of Components
Sources

Berlin-Chemie/Menarini Pharma GmbH, Gedeon Richter, Krka, Lek (Novartis/Sandoz), Stada AG (Stada CIS) and Verofarm

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos